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Abstract
Background: The transcatheter aortic valve implantation (TAVI), a minimally invasive surgical procedure to treat
patients with severe symptomatic aortic stenosis, showed a rapid diffusion in Germany compared to the international
level. The aim of this study is to identify and analyze factors affecting the implementation and diffusion of the
procedure in hospitals using a qualitative application of the diffusion of innovations theory.
Methods: We conducted problem-centered interviews with cardiologists and cardiac surgeons working in German
hospitals. The multi-level model “diffusion of innovations in health services organizations” developed by Greenhalgh et
al. was used to guide the research. Data was analyzed using content and a thematic analysis.
Results: Among the ten participants who were interviewed, we found both barriers and facilitators related to the
innovation itself, system readiness and antecedents, communication and influence, and the outer context. Key issues
were the collaboration between cardiologists and cardiac surgeons, reimbursement policies, requirements needed to
conduct the procedure, and medical advantages of the method.
Conclusions: The findings show that there are multiple factors influencing the diffusion of TAVI that go beyond the
reimbursement and cost issues. The diffusion of innovations model proved to be helpful in understanding the different
aspects of the uptake of the procedure. A central theme that affected the implementation of TAVI was the
collaboration and competition between involved medical departments: cardiology and cardiac surgery. Against
this background, it seems especially important to moderate and coordinate the cooperation of the different
medical disciplines.
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Background
If medical innovations show a positive effect on the quality
of care and/or the treatment cost, they can lead to an in-
creased productivity of hospitals and healthcare systems.
However, if innovations in healthcare show positive out-
comes, they seem to spread relatively slowly [1]. The rea-
sons for a fast or slow diffusion are both complex and
multilayered. It could be assumed, for example, that de-
vices or drugs with strong clinical evidence spread faster
than those with lagging evidence. However, several studies
have proven that that is not always the case [2–4].
The transcatheter aortic valve implantation (TAVI)1 is a
relatively new method to treat patients with severe symp-
tomatic aortic stenosis (AS). TAVI represents a minimally
invasive alternative in comparison to the current standard
AS treatment, which is surgical aortic valve replacement
(AVR). With TAVI, a replacement valve is introduced
through an artery via a small incision, thus requiring no
surgery. Supported by results of randomized trials, TAVI
can be seen as “the new standard of care for patients with
symptomatic AS who are deemed ‘inoperable’” [5, 6]. The
first-in-man implantation was performed in 2002, and by
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2007, two devices were certified in Europe [7]. In 2010,
the method was completely reimbursed by the German
therapy-specific diagnosis-related group (DRG). In the
same year, the first results of a randomized controlled trial
comparing TAVI versus medical therapy versus AVR were
released [5]. Since 2007, the procedure has shown signifi-
cant adoption rates in Germany compared to the inter-
national level. In Europe, almost 45.9 % of all TAVI have
been implanted in German hospitals, thus making it the
largest market in the EU [8, 9]. Starting with a total of 68
implanted devices, this amount had increased up to
10,814 by 2013. The same is true considering centers per-
forming the method: With 22 centers in 2008, and 93 in
2013, Germany had the most centers in Europe (see
Table 1).
This development has been repeatedly criticized [8, 10].
Critics argue that the method had begun to diffuse widely,
while at the same time, valid clinical evidence was still
missing, especially in the consideration of which patients
should be receiving the intervention [8]. With increasing
uptake, TAVI was also performed by hospitals which did
not meet the recommendations of the national and
European cardiac and cardiothoracic societies and asso-
ciations regarding requirements necessary for conduct-
ing the method [9–11]. This includes the involvement
of a “Heart-Team” involving cardiologists, cardiac sur-
geons, and anesthetists and having an on-site depart-
ment of cardiac surgery. Storz-Pfennig et al. summarize
the development: “The criticisms support the view that
the technology was, and still is being, used beyond
proper indications and in treatment facilities not ad-
equately equipped for emergencies.” [9]. A new guide-
line passed by the German Federal Joint Committee in
January 2015 has set limits for hospitals performing
TAVI: Only those that have a department of cardiology
and cardiac surgery shall be allowed to provide the
intervention [12].
Improving the diffusion of cost-effective technologies,
while at the same time preventing the uptake of medical
technologies that are of “doubtful value” for healthcare
systems, is the purpose of health technology assessment
(HTA) [13]. HTA is the systematic evaluation of effects
and impacts of health technology from a multidisciplin-
ary perspective covering medical, social, legal, ethical,
and economic aspects. The approach has originally
emerged as a response by policy makers to the uncon-
trolled diffusion of medical devices and products [14].
Diffusion research, including drivers and barriers affecting
the uptake of health technologies, is an important aspect
of HTA. In turn, the healthcare sector has played a
dominant part in the history of implementation and dif-
fusion research. The pioneer work of Coleman, Katz,
and Menzel, who studied the spread of a new drug
among physicians, marks the first of numerous studies
analyzing the factors and determinants influencing the
adoption, implementation, and the spread of innova-
tions in the healthcare sector [15]. Recent studies de-
scribe four core domains playing a role within the
implementation and diffusion process: the structural,
organizational, individual, and innovation level [16, 17].
Each level encompasses multiple determinants affecting
the implementation success and the diffusion rate. For
example, Fleuren et al. found 50 potentially relevant de-
terminants of innovation processes [17]. Following
Blume’s argumentation that every medical innovation
has its own “career,” these determinants differ with re-
spect to the research subject [18].
Several theories and models can be applied to better
understand the implementation and diffusion of innova-
tions in healthcare—most notably, Everett M. Rogers’
Diffusion of Innovations (DOI) theory [19], as well as
the diffusion of innovations model described by Green-
halgh et al. [20]. Both have been adopted in numerous
studies analyzing the implementation and diffusion of
innovations in healthcare (see, for example, [1, 21, 22]).
Roger’s DOI theory has been picked up by multiple re-
searchers in various contexts and disciplines to explain
the spread of emerging innovations. In short, the ap-
proach explains why certain innovations spread more
easily than others. For instance, the individual’s per-
ceived attributes of an innovation (relative advantage,
complexity, compatibility, observability, and trialability)
account for 49 to 87 % of the adoption variation [19].
The nine components of the multi-level model detailed
below, described by Greenhalgh et al., focus mainly on
the healthcare sector. (1) The innovation itself: As
shown by Rogers, the innovation’s attributes can explain
much of the variance in the adoption rate of innovations.
In addition to the five core attributes described in the
DOI theory, Greenhalgh et al. add the potential of re-
invention, risk, task issues, ease of use, knowledge re-
quired to use it, and support [20]. (2) The potential
adopter: Adoption is considered as an active process;
one’s past experiences affect the adoption decision, and
Table 1 Diffusion of TAVI in Germany from 2006 to 2013 [30–33]
2006 2007 2008 2009 2010 2011 2012 2013
Total amount of TAVI 68 239 1,463 3,411 5,799 7,681 9,271 10,814
Amount of centers 2 10 22 61 80 90 91 93
Centers performing TAVI without an on-site cardiac surgery - - - - 14 18 18 17
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persons are more or less risk-averse. (3) Communication
and influence: The adoption decision can be actively in-
fluenced by opinion leaders or champions, or it can
occur by copying others. (4) System antecedents of
innovation include structural factors (e.g., the size of an
organization), the capacity for new knowledge (e.g.,
pre-existing knowledge or skills), and the context for
change (e.g., risk-taking climate). (5) System readiness
for innovation covers the “organization’s ability to
adopt a particular innovation” [23]. (6) The outer con-
text: Both the economic and social situation, as well as
competing companies and institutions, can have an ef-
fect on adoption decision. (7) The process of assimila-
tion: Innovations “have a ‘hard core’ (the irreducible
elements of the innovation itself ) and a ‘soft periphery’
(the organizational structures and systems required
for the full implementation of the innovation)” [20];
adopting the soft elements can result in a complex and
non-linear process. (8) The implementation process: A
successful implementation can be affected by dedicated
resources or external collaboration. (9) The linkage be-
tween the components.
One explanation for the rapid diffusion of TAVI is
found in the reimbursement policies and, accordingly, the
cost of the procedure [8–10]. It can be assumed, however,
that this is only one factor among many others. The main
purpose of our study is to identify the factors affecting the
uptake of TAVI. The case of TAVI can provide deeper in-
sights into the adoption, implementation, and diffusion of
medical innovations in hospitals in general.
Method
Data collection
We used the model provided by Greenhalgh et al. to
guide our research and to analyze the data. Based on
these theoretical implications, along with the fact that
qualitative approaches have continuously gained rele-
vance when studying complex interventions [24], we
used problem-centered interviews to gather our data
[25]. The problem-centered interview represents a dis-
cursive procedure “to gather objective evidence on hu-
man behavior as well as on subjective perceptions and
ways of processing social reality” [25]. The method was
developed by Witzel, who summarizes it as “a theory-
generating method that tries to neutralize the alleged
contradiction between being directed by theory or being
open-minded so that the interplay of inductive and de-
ductive thinking contributes to increasing the user’s
knowledge.” [25]. Though we do not know any compar-
able work using this instrument to study the adoption,
implementation, and diffusion of innovations in health-
care, the method has been used in market research to
gain a better understanding of factors influencing the
adoption of innovative products. The interviews were
structured as follows: A pre-formulated introductory
question or statement (“Please tell us about the imple-
mentation process of TAVI within your hospital; from
the very beginning until today.”) stimulates the inter-
viewees to talk about the implementation process within
the organization. While the interviewer only plays a pas-
sive role during the first phase of the interview, the sec-
ond phase consists of general exploration and ad hoc
questions. The interviewer “can ask questions which
allow the thread of the story to be further spun” [25]. To
compare the interviews with each other, we used an
interview guide based on the theoretical framework and
on additional material about the research subject. The
interview guide was piloted in two interviews prior to data
collection. All interviews were conducted in German, and
all quotes cited within this paper were translated.
Sample size and recruitment
While there is no general agreement regarding the sam-
ple size for the problem-centered interview, between 7
to 30 interviews is suggested based on previous research
[26]. We did not define a specific sample size a priori;
the sampling of new participants continued until we
achieved redundancy. We interviewed cardiologists and
cardiac surgeons working in hospitals who also have ex-
perience in using TAVI for at least 1 year. To identify
potential participants, a list of hospitals using the pro-
cedure was drawn from the hospital’s quality reports2.
The respondents were chosen purposefully and ran-
domly. Because it proved difficult to include partici-
pants, we did not aim for maximum variation. The
purposeful sampling only covered the size of the hos-
pital, using the amounts of beds as a proxy, and the hos-
pital type (whether it was a university hospital or not).
The potential participants were contacted by email,
which contained an informational document explaining
the aim and the method of the study and that the identi-
fication of participating persons will not be possible after
the analyses. Depending on the time schedule of the in-
terviewees, either a face-to-face or a telephone interview
was set up. The interviews were carried out by a trained
researcher between February and March 2014, digitally
recorded and transcribed verbatim.
Analysis of the data
Each transcript was analyzed using qualitative content
analysis, which was then organized in four steps: (1) There
was a familiarizations process with the data to gain a dee-
per understanding. This included reading through the
transcript multiple times. (2) Using an inductive and de-
ductive approach, categories were generated that helped
to compromise the data without losing information.
Based on the model by Greenhalgh et al. [20], we set
up an initial coding scheme that used all of the above
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mentioned nine components as main categories for the
coding process. (3) We used an inductive approach to de-
veloped sub-categories based on the data and to ensure
that all aspects were covered. After coding approximately
40 % of the data, we revised and refined the coding
scheme. The final coding scheme did not cover all main
categories. We focused on the innovation itself, communi-
cation and influence, system readiness, system antecedent,
and the outer context. (4) Lastly, the interviews were ana-
lyzed using MAXQDA11. The development of the coding
scheme and the analysis of the gathered data were under-
taken by the researcher who conducted the interviews.
Anonymization
Though anonymization does not receive much attention
in qualitative studies [21], it has to be seen as a central
aspect and leads to multiple challenges. On the one
hand, an insufficient anonymization can cause harm to
the participants and the organizations they work for. On
the other hand, too much anonymization affects the re-
sults of the research process [21]. We decided to remove
all evidence that could lead to an identification of either
the interviewee or the hospital he or she works for. Since
only around 4 % of all hospitals in Germany work with
TAVI, we deleted whole passages and used synonyms.
The deletion includes such information as hospital size,
type of hospital, the date the procedure had been imple-
mented, the sex of the participant, and the hierarchical
position, as well as any references that would indicate
the location of the clinic.
Results
In total, we conducted ten interviews across nine sites,
three of which were university hospitals. Eight interviews
were face-to-face and two via telephone. The interviews
lasted between 20 to 35 minutes, the average time length
being approximately 25 min. The sample is characterized
by an over representation of cardiologists (nine out of
ten respondents). The inductive approach revealed sev-
eral factors that were mentioned by the interviewees
within the following themes: collaboration between car-
diologists and cardiac surgeons, reimbursement policies,
requirements and skills needed to conduct the proced-
ure, and medical advantages of the method. All of these
themes are reflected by the model. We could identify
potential facilitators and barriers to the adoption, imple-
mentation and diffusion related to the innovation itself,
communication and influence, system readiness for
innovation and system antecedents for innovation, the
implementation process, and the outer context.
Innovation level
After the initial knowledge phase and getting in touch
with the procedure for the first time, most participants
rejected TAVI: “What nonsense. It cannot work this
way.” (Cardiologist 4). After reconsideration and further
discussion of TAVI, e.g., at internal meetings, the deci-
sion for implementation was made.
The respondents described multiple advantages of TAVI
compared to the standard surgical procedure and drug
treatment. Our interviewees generally mentioned medical
outcomes and the improved quality of life of patients who
underwent TAVI as an advantage. Several participants
gave examples of how fast the patients recovered after the
intervention and that the patients were able to leave the
hospital much earlier compared to the standard surgery.
In terms of medical outcomes, the results were not only
perceived as better compared to the “classical” surgical
procedure but were also directly visible to the physician
and to the patient, as well as his or her relatives.
“You must have seen this, indeed. Patients are
responsive right after the procedure, have little pain,
at worst a bit of a pain in the groin, and can be
mobilized in the evening or the next day… But they
are responsive directly after the procedure, can eat,
drink, talk with their families. They can be mobilized
on the first day, third day down from the ICU, out of
the house on the fifth day. You won’t find this with
any other surgical procedure.” (Cardiologist 3)
“But it is an intervention in which the patient is
basically walking around the next day. And with
heart surgery that is, of course, very, very different.
That’s it, especially for older persons… And I think
the 80-year-old patient must quickly get out of the
hospital and back into his environment and considering
this, such a method has, of course, a huge advantage.”
(Cardiologist 1)
One participant perceived the procedure as “highly
complex” (cardiologist 7), a view that was shared. Even
though TAVI proved compatible with existing practices,
the method was seen as difficult to perform. Responses
commonly indicated that TAVI required new knowledge
and intensive training.
“But at the time we introduced that, when the
treatment was new, each component had to be
learned first […]” (Cardiologist 5)
“This is certainly a different dimension compared to a
normal coronary intervention because you work with
much, much thicker systems in marginal thin vessels.”
(Cardiologist 5)
The respondents felt that TAVI has a steep learning
curve. As the participant below estimated, it takes around
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50 to 60 interventions to master the procedure; a number
that was verified by another interviewee.
“I would say, until someone can reasonably
do it, minimum numbers are not defined, but
I think you need about 50 to 60 procedures…”
(Cardiologist 4)
The risk of the procedure was linked to the available
evidence. The respondents perceived the evidence base
as good concerning patients aged 75 and older but found
it not sufficient regarding younger patients. They arrived
at the conclusion that the standard surgical procedure
was still seen as superior with respect to this patient
group. The criticism was driven by the lack of empirical
knowledge concerning the duration of the implanted
aortic valves.
Communication and influence
The physicians referred to two main sources of informa-
tion. They consulted professional journals and national
and international congresses, as well as opinion leaders
at both the national and international level or “frontiers”
as one interviewee said. Some of the respondents ac-
tively established contact with either one of the opinion
leaders or with a medical device company in order to
learn about the procedure. In the case of the medical de-
vice company that developed the artificial valves, they
offered information and training sessions for the staff in-
volved and promoted the implementation of the method.
In one case, an interviewee referred to a conflict be-
tween two of the involved opinion leaders, where the
cardiac surgeon rejected the method and the cardiologist
supported it. The head physicians of the department of
cardiology and cardiac surgery were reported to have
played key roles in the implementation within the hos-
pital, whereas support by the administration was only re-
ported in one case. While some physicians stated that
patients explicitly asked for TAVI instead of the standard
treatment, this was perceived as rarely the case. More
common seemed to be the fact that relatives and friends
heard about the procedure.
“The patients who inform themselves and ask for it
are those to whom one would offer it reluctantly
because these are the younger patients…”
(Cardiologist 4)
Two respondents mentioned that the hospitals they
work for organize events to facilitate the dissemination
of TAVI, either targeting general practitioners or pa-
tients. In contrast, one participant emphasized that there
are no efforts in “advertising.”
System readiness and system antecedents
Pressure for change was widely reported by the respon-
dents. The interviewees named a combination of differ-
ent aspects as reasons for this pressure, most notably
the organizational self-image, as well as competition be-
tween hospitals. Hospitals that consider themselves as
innovative were reported to having wanted to implement
the procedure and be among the early adopters, as the
following respondent replied:
“Then there are early adopters, who quickly adopt
good and promising practices, that’s us. And then
there are the laggards, late adopters, and that is what
we do not want to be.” (Cardiologist 3)
The interviewees referred to organizational require-
ments needed to implement the procedure. In multiple
interviews, the heart team was mentioned as a central
player in considering the implementation of the method.
The views of the participants differ considering the com-
position of the heart team. While in most interviews it
was mentioned that a cardiac surgeon, an interventional
cardiologist, and an anesthesiologist should be present
during the procedure, the comment below illustrates
that reality could look different:
“…the heart team should not exist merely on paper.
In other words, that there is a surgeon somewhere
who is only on standby, or who says ‘yeah,
sure’.”(Cardiologist 8)
The opinions about the required staff changed accord-
ing to the type of hospital. Interviewees working in uni-
versity hospitals found it inevitable to have an in-house
department for cardiovascular surgery, while those
working in smaller and specialized hospitals did not
share this view. Hospitals without such a department
sought expertise from outside and hired an external sur-
geon especially for TAVI.
“This cannot be managed by a normal house where
only standard operations are conducted and without a
cardiac surgery. You have to say this. And houses that
do it, which have the logistics, emphasize the safety
aspect and that they cover the all safety issues…”
(Cardiologist 4)
The most evident factor mentioned by nearly all inter-
viewees was the internal collaboration with other med-
ical departments, most notably between cardiologists
and cardiac surgeons. Many respondents described this
struggle as a factor influencing the adoption decision
and slowing down or interrupting the implementation
process, as the statements below indicate:
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“These are the nuts and bolts… Because, often the
teamwork of cardiologists and cardiac surgeons is not
given…This is a major problem because the
interventional cardiology has expanded into many
areas of heart surgery…” (Cardiologist 5)
“Because, especially in the initial phase… we failed
because of the resistance of the cardiac surgery
without which, of course, it didn’t work at that time,
or still does not work.” (Cardiologist 1)
The respondents commented that TAVI created an
issue of competence. While the cardiologists felt eager
to implement the method, the cardiac surgeons were de-
scribed as reluctant and refusing. Some interviewees felt
that this was because of a “restructuring” of those two
medical disciplines. More and more treatments, which
originally belonged to the field of work of the cardiac
surgeons, have now become the responsibility of the car-
diologists, as the following statement indicates:
“With the introduction, I think there was concern in
all houses… I believe this was the case everywhere…
It’s psychological. You delve into the innermost of the
heart or in the core competence of cardiac surgery.
The colleagues got used to the fact that cardiologist
do more and more. They have taken pacemakers and
defibrillators, all previously done by surgeons… But if
someone wants to have a new aortic valve, then he
needs to ask us.” (Cardiologist 4)
After the conflict had been solved, one respondent felt
that “…the TAVI program has actually resulted in a
much closer cooperation with the cardiac surgery.” (Car-
diologist 1). The interviewee described that after initial
denial, a restructuring took place which created space
for new cooperation between both departments. The im-
plementation phase took about 1 year, as some of the
participants confirmed.
The outer context
Concerning the extra-organizational context, the respon-
dents described economic as well as social influences on
the adoption decision. As mentioned above, there is not
only an ongoing debate about TAVI in journals but in pub-
lic media as well. In particular, the public debate was per-
ceived as generally useful, although misguided. While one
respondent described the discourse as “one-sided,” focusing
either on cost issues of TAVI or on its medical outcomes.
The statement below indicates yet another perception:
“I’ve perceived the discussion as quite controversial
and as it should be. So I thought that this was really
impressive, the way that it was discussed within the
society… What issues have been addressed and what
has been discussed. I haven’t experienced this with
other procedures….. Probably because it was done too
often.” (Cardiologist 3)
The approval system for medical devices in Europe
and the reimbursement system in Germany, often de-
scribed as “innovation friendly” in comparison to the US
medical device regulation, was a theme often brought up
during the interviews. Being able to receive reimburse-
ment at an early stage was regarded as one of the main
drivers facilitating the diffusion of TAVI. The DRG rate
was perceived as high, but most of the participants did
not see TAVI as a way to generate as much profit as ar-
gued in the public debate. Some interviewees did say,
however, that it could be a way to generate money if
done in large amounts and, therefore, could be interesting
for hospitals. The missing quantitative limitation regard-
ing the maximum and minimum amount of procedures
and the fact that no mandatory requirements concerning
the diagnosis and infrastructure of hospitals using TAVI
exist were also mentioned as factors positively influencing
the diffusion rate.
Discussion
The aim of this study was to explain the vast uptake of
TAVI within the German healthcare system. Based on
problem-centered interviews, it did this by applying the
“innovation in health service organizations” model de-
veloped by Greenhalgh et al. to an innovative cardiac
intervention in hospitals. The model was found useful to
guide the research process and to structure the analysis.
While the public debate centers on reimbursement pol-
icies and cost issues as main drivers for the diffusion,
this study showed that multiple factors affect the spread
of the procedure. Besides reimbursement policies and
cost issues, the most prominent themes were the collab-
oration between cardiologists and cardiac surgeons, re-
quirements needed to conduct the procedure, and the
medical advantages of the method.
The collaboration between cardiologists and cardiac
surgeons was identified as a factor negatively affecting
the implementation and diffusion speed. It seemed that
this “frozen conflict” with respect to shifting compe-
tences has reached a new level with TAVI as several re-
spondents perceived. In some cases, the implementation
of TAVI resulted in a better collaboration between both
departments. The interviews indicate that this depended
on central actors, which underscores previous research
[22]. Champions, eager to implement the method, facili-
tated the dialogue between both departments and took
initiative to drive the process forward. However, if the bal-
ance of power favored the standard treatment instead of
TAVI, it needed stimuli like a staff turnover to facilitate
new approaches. These findings suggest that moderation
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could be needed to foster the implementation process and
to mediate between different interests. In all our cases, the
procedure was implemented sooner or later, implying that
if conflicts of interest existed, they were solved. The inter-
views suggest that cardiologists had more bargaining
power. A reason for this could be the fact that the inter-
vention is indicated by the cardiologists, and patients
undergo surgery only if the cardiologist sees that as an op-
tion. Another reason lies in the possibility to hire expertise
from the outside, as was mentioned in one of the inter-
views. Even though prevailing issues have been solved in
all cases, it could lead to further dissent in the future due
to expanding indications, as comments regarding this con-
flict imply.
According to the recommendations of German and
international cardiac and cardiothoracic societies and as-
sociations, the decision whether TAVI is an option for
the patient should be made by a heart team comprised
of cardiologists, a cardiac surgeon, and anesthesiologists.
If required, this also includes other specialists such as
vascular surgeons or angiologists [27]. As the interviews
indicate, this is not a given in all hospitals (see also
Table 1). This refers to what Greenhalgh et al. entitle as
“assimilation.” Innovations consist of a “hard core,” the
innovation itself, and a “soft periphery” [20], which in-
clude organizational structures necessary to implement
the innovation. Previous results have shown that the
more adaptable the “soft periphery” is, the more likely
an innovation will be adopted [20]. If the soft periphery,
in the case of TAVI having a surgical department on
site3, is no longer perceived as necessary, this could fur-
ther increase the diffusion of the procedure. As the re-
spondents mentioned during the interviews and as
current debates suggest, this requirement is more and
more questioned.
With respect to the attribute of relative advantage,
which is described as “the degree to which an innovation
is perceived as being better than the idea it supersedes”
[19], medical advantages proved to be a strong driver.
We could show that the procedure was perceived as
significantly better. Still, this is only true for the current
indication: older patients with severe symptomatic AS
who are not suited for conventional procedures [10].
Considering the age of patients undergoing TAVI, the
recommendations of the national and European cardiac
and cardiothoracic societies and associations suggest a
minimum age of 75 [10]. In the group of patients under
the age of 75, the surgical intervention was considered
superior to TAVI, although the respondents predicted
changing recommendations for the near future. Experi-
menting with an innovation on a limited basis was labelled
“trialability” by Rogers [19]. Even though experimenting
with new techniques and procedures bears a high degree
of risk, trialability can have an important impact on the
adoption decision of medical devices and facilitate the up-
take [28]. While a patient’s attitudes and beliefs can have
an influence on the adoption decision and the implemen-
tation, patients either actively request new treatment
methods or distrust procedures and reject them [29].
While the patient’s perception of TAVI has to be consid-
ered as an innovation-level factor, it can affect the physi-
cian’s adoption decision [16]. As pointed out by Chaudoir
et al., “the patient-level factor encompasses patient charac-
teristics such as health-relevant beliefs, motivation, and
personality traits that can impact implementation out-
comes.” [16].
Recommendations for research and practice
This study raises additional questions that have to be in-
vestigated further. The ongoing debate about the indica-
tions for TAVI, as well as the requirements necessary to
perform the procedure, requires more research from dif-
ferent angles. For instance, a discourse analysis could
provide additional insights about the balance of power.
This is also interesting with respect to the conflict be-
tween cardiologists and cardiac surgeons. Further studies
should focus particularly on the question of how, and in
which ways, new medical devices, procedures, and their
diffusion affects the collaboration and interaction of
medical professionalism and work processes. From a
practical point of view, different factors that were dis-
cussed within this study provide opportunities to influ-
ence the implementation and diffusion of the procedure.
Moderation could be a way to support the implementa-
tion process. Focus should also be placed on conflicts
about competences and responsibilities as they could
lead to negative implementation outcomes and, as a
worst case, cause harm to the patients.
Limitations
This study focuses only on cardiologists and thoracic
surgeons working in hospitals. Further interviews with
administrative staff, like medical or commercial direc-
tors or nursing staff, could provide further insights
into the implementation processes. In addition, the re-
sults are mainly from the cardiologists’ point of view,
and hospitals refusing to implement TAVI respectively
non-adopters or “negative cases” were not included.
This derived from the fact that we faced multiple chal-
lenges during the recruitment. Firstly, the subject of
our research is considered controversial at the na-
tional and international level, which seemed to affect
the willingness to participate in a negative way. Secondly,
an analysis of the hospital’s quality reports shows the im-
plementation of the method was consistent during the
analysis period, making it hard to identify “negative cases.”
Thirdly, the method of problem-centered interviews, in
particular the narrative beginning, was rather unknown to
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the respondents. This could have caused irritation and
lead some to reject participation. The respondents were
also asked to recall events and discussions form the past,
in some cases covering several years, which could have a
negative effect on the level of detail. Even though anonym-
ity was ensured prior to and after the interview, the an-
swers given bear the risk of social desirability. The
respondents may have given answers that they felt were
pleasing to the interviewer.
Conclusions
This paper has, based on problem-centered interviews,
illustrated factors affecting the adoption, implementa-
tion, and diffusion of TAVI within German hospitals.
According to the multi-level model described by
Greenhalgh et al., many interacting factors influence
the adoption decision, the implementation, and the dif-
fusion of TAVI in Germany. Summarizing the results,
we found that, on the innovation level, relative advan-
tage was not only expressed in terms of medical advan-
tages and social prestige but reimbursement also
positively affected the adoption decision. The same is
true with respect to the attribute of complexity: Even
though the intervention was described as complex, this
seems to have a positive rather than a negative effect
on the adoption decision. According to the domain of
communication and influence, opinion leader could be
identified on the system level. The implementation of
the procedure was driven by champions, typically head
physicians of the department of cardiology, while car-
diac surgeons took the role of gatekeepers. The readi-
ness for innovation was reflected on the system and
organizational level and referred to the conflict/cooper-
ation between cardiologists and cardiac surgeons. A
well-established cooperation supported the implemen-
tation process, whereas an internal conflict interrupted
it. We could identify two system antecedents for
innovation that influenced the success of the imple-
mentation: organizational self-image and the size/type
of the hospital. Reimbursement policies and the public
debate affected the diffusion of the method as external
factors. The most dominant themes proved to be the
medical advantages of the procedure, the fact that it
was quite easy to have TAVI reimbursed, and the co-
operation and competition between medical depart-
ments and disciplines. Interestingly, TAVI diffused
relatively quickly despite major challenges and hin-
drances that occurred during the diffusion process.
Most notably, this includes the conflict between cardi-
ologists and cardiac surgeons regarding responsibilities
and competences and, as a consequence, due to the
controversial debate. Taking into consideration the pro-
fessional discourse about TAVI, further research from
different disciplines is needed not only to guarantee a
safe and controlled diffusion of TAVI but also other
emerging procedures and innovations.
Endnotes
1Also called transcatheter aortic valve replacement
(TAVR).
2From 2005 on, each acute hospital in Germany is le-
gally obligated to publish a structured quality report on
a regular basis containing information about operations
and procedures that were performed. Only hospitals
with more than five cases are included.
3In this context, it is important to distinguish between
an “on-site surgery” which guarantees surgical backup
and an “on-site surgical department” going beyond that
aspect [34].
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